Skip to main content

Advertisement

Erratum: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

Article metrics

  • 1229 Accesses

The original article was published in Diabetology & Metabolic Syndrome 2014 6:104

Erratum

After publication of this manuscript [1], we noted errors to the labels of Fig. 7. The Y-axis of panel C was incorrectly labelled as “Plasma Adiponectin, ng/ml” instead of “PEPCK, % of Vehicle”. (Please see a corrected version of Fig. 7 below).

Fig. 7
figure1

Impact of timed daily bromocriptine or vehicle administration on gluconeogenic pathway regulators – FOXO1 phosphorylated at Ser256 (Panel a), glucose-6-phosphatase (Panel b), and PEPCK (Panel c). Proteins we quantified by Western blotting. Values are means ± SEM of 8 animals in each group. *Difference is statistically significant; P values are noted under each panel

Reference

  1. 1.

    Ezrokhi M, Luo S, Trubitsyna Y, Cincotta AH. Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr. 2014;6:104.

Download references

Author information

Correspondence to Anthony H. Cincotta.

Additional information

The online version of the original article can be found under doi:10.1186/1758-5996-6-104.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark